2 Reasons to Like EXAS (and 1 Not So Much)
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
2 Oversold Stocks Ready to Bounce Back and 1 to Approach with Caution
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
2 Small-Cap Stocks on Our Watchlist and 1 to Ignore
1 Healthcare Stock on Our Watchlist and 2 to Turn Down
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
1 Stock Under $50 to Target This Week and 2 to Turn Down
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...